申请人:MEIJI SEIKA PHARMA CO., LTD.
公开号:US20160024090A1
公开(公告)日:2016-01-28
A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I):
wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC
1-6
alkyl; C represents benzyl, H or SO
3
M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C
1-6
alkyl or acyl; Rc represents C
1-6
alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C
1-6
alkyl, O═, or Rg-(CH
2
)
0-3
—, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO
2
S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C
1-6
alkyl or MO—; Re and Rf represent H or C
1-6
alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.
一种二
氮杂双
环辛烷化合物,其为
β-内酰胺酶抑制剂,由以下式子(I)表示:其中,A代表Ra(Rb)N-或RcO-;B代表NH或NC1-6烷基;C代表
苄基、H或SO3M,其中M代表H、无机或有机阳离子;Ra和Rb代表H、C1-6烷基或酰基;Rc代表C1-6烷基或杂环基;A未被取代或被0至4个Fn1取代,其中Fn1代表C1-6烷基、O═或Rg-(
CH2)0-3-,其中Rg代表杂环基、
苯基、杂环芳基、酰基、RdO2S-、Re(Rf)N-、Re(Rf)NCO-、ReO-、ReOCO-或保护基,其中Rd代表C1-6烷基或
MO-;Re和Rf代表H或C1-6烷基,Ra和Rb之间、Rc和B之间或Re和Rf之间可以形成至少一个含有
氮原子的杂环。